Related Experiment Videos
Serotonergic sensitivity in borderline personality disorder: preliminary findings
E Hollander1, D J Stein, C M DeCaria
1Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York.
The American Journal of Psychiatry
|February 1, 1994
Summary
Borderline personality disorder patients experienced reduced anger and fear after m-chlorophenylpiperazine (m-CPP) administration. This suggests potential serotonergic system dysfunction in BPD.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Borderline personality disorder (BPD) is a complex mental health condition.
- Serotonergic pathways are implicated in mood and emotional regulation.
Purpose of the Study:
- To investigate the effects of m-chlorophenylpiperazine (m-CPP) on emotional state and neuroendocrine responses in BPD patients.
- To explore potential serotonergic system dysfunction in individuals with BPD.
Main Methods:
- A double-blind, placebo-controlled study involving 12 BPD patients and 15 healthy controls.
- Administration of single oral doses of m-CPP and placebo.
- Assessment of emotional changes (anger, fear) and neuroendocrine markers (cortisol, prolactin).
Main Results:
- BPD patients reported decreased anger and fear following m-CPP.
- A significant proportion of BPD patients experienced dissociative symptoms ('spacy,' 'high,' depersonalization/derealization).
- Male BPD patients exhibited higher cortisol levels and blunted prolactin responses compared to male controls after m-CPP.
Conclusions:
- The findings suggest a role for serotonergic dysfunction in the pathophysiology of BPD.
- m-CPP's effects on emotional and neuroendocrine measures provide insights into BPD.
- Further research is warranted to explore targeted serotonergic interventions for BPD.